Bottom line
Is HRTS a good fund? The bottom line
HRTS is a managed health care sector ETF from Innovator.
Its expense ratio is 0.75% — about $75 a year on every $10,000 invested, cheaper than 66% of health care sector funds we track.
It returned +23.6% over one year (as of Dec 31, 2025, per its prospectus).
With $51.9 million in net assets and 45 holdings, its largest position is Eli Lilly & Co (11.5%) and the top 10 make up 49.1% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 57% top-holdings overlap).
Updated Nov 19, 2026
What HRTS invests in
Tema Heart & Health ETF ( formerly, Tema GLP-1, Obesity & Cardiometabolic ETF ) (the Fund) seeks to provide long-term growth of capital.
Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions (CDC). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms…
From the fund's prospectus (filed Jun 29, 2026).
HRTS performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| HRTS | +23.6% | — | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What HRTS costs
On a $10,000 investment, HRTS's 0.75% expense ratio costs about $75 a year. The prospectus estimates $1,168 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
HRTS top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co LLY | 11.52% |
| 2 | UnitedHealth Group Inc UNH | 5.24% |
| 3 | Novo Nordisk A/S NOVOB | 5.24% |
| 4 | Roche Holding AG RHHBY | 4.50% |
| 5 | Merck & Co Inc MRK | 4.27% |
| 6 | AstraZeneca PLC AZN | 4.00% |
| 7 | Thermo Fisher Scientific Inc TMO | 3.97% |
| 8 | Johnson & Johnson JNJ | 3.59% |
| 9 | Gilead Sciences Inc GILD | 3.43% |
| 10 | Novartis AG NOVN | 3.38% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 49.1% of the fund. See all top 25 holdings and asset mix →
Alternatives to HRTS
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 57% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 59% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 57% | Compare |
| iShares | IXJ iShares Global Healthcare ETF | 0.38% | 64% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 56% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 57% | Compare |